FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016263931> ?p ?o ?g. }

• W2016263931 endingPage "144" @default.
• W2016263931 startingPage "144" @default.
• W2016263931 abstract "Background: Tobacco dependence is a chronic, relapsing condition that may require extended treatment. Objective: To assess whether extended-duration transdermal nicotine therapy increases abstinence from tobacco more than standard-duration therapy in adult smokers. Design: Parallel randomized, placebo-controlled trial from September 2004 to February 2008. Participants and all research personnel except the database manager were blinded to randomization. (ClinicalTrials.gov registration number: NCT00364156) Setting: Academic center. Participants: 568 adult smokers. Intervention: In an unstratified small block–randomization scheme, participants were randomly assigned to standard therapy (Nicoderm CQ [GlaxoSmithKline, Research Triangle Park, North Carolina], 21 mg, for 8 weeks and placebo for 16 weeks) or extended therapy (Nicoderm CQ, 21 mg, for 24 weeks). Measurements: The primary outcome was biochemically confirmed point-prevalence abstinence at weeks 24 and 52. Secondary outcomes were continuous and prolonged abstinence, lapse and recovery events, cost per additional quitter, and side effects and adherence. Results: At week 24, extended therapy produced higher rates of point-prevalence abstinence (31.6% vs. 20.3%; odds ratio, 1.81 [95% CI, 1.23 to 2.66]; P = 0.002), prolonged abstinence (41.5% vs. 26.9%; odds ratio, 1.97 [CI, 1.38 to 2.82]; P = 0.001), and continuous abstinence (19.2% vs. 12.6%; odds ratio, 1.64 [CI, 1.04 to 2.60]; P = 0.032) versus standard therapy. Extended therapy reduced the risk for lapse (hazard ratio, 0.77 [CI, 0.63 to 0.95]; P = 0.013) and increased the chances of recovery from lapses (hazard ratio, 1.47 [CI, 1.17 to 1.84]; P = 0.001). Time to relapse was slower with extended versus standard therapy (hazard ratio, 0.50 [CI, 0.35 to 0.73]; P < 0.001). At week 52, extended therapy produced higher quit rates for prolonged abstinence only (P = 0.027). No differences in side effects and adverse events between groups were found at the extended-treatment assessment. Limitation: The generalizability of the findings may be limited because participants were smokers without medical comorbid conditions who were seeking treatment, and differences in adherence across treatment groups were detected. Conclusion: Transdermal nicotine for 24 weeks increased biochemically confirmed point-prevalence abstinence and continuous abstinence at week 24, reduced the risk for smoking lapses, and increased the likelihood of recovery to abstinence after a lapse compared with 8 weeks of transdermal nicotine therapy. Primary Funding Source: National Institutes of Health." @default.
• W2016263931 created "2016-06-24" @default.
• W2016263931 creator A5017029517 @default.
• W2016263931 creator A5026614969 @default.
• W2016263931 creator A5040185719 @default.
• W2016263931 creator A5061725200 @default.
• W2016263931 creator A5061994382 @default.
• W2016263931 creator A5065583926 @default.
• W2016263931 creator A5082109429 @default.
• W2016263931 date "2010-02-02" @default.
• W2016263931 modified "2023-09-27" @default.
• W2016263931 title "Effectiveness of Extended-Duration Transdermal Nicotine Therapy" @default.
• W2016263931 cites W100025541 @default.
• W2016263931 cites W1593493925 @default.
• W2016263931 cites W1955803833 @default.
• W2016263931 cites W1982619758 @default.
• W2016263931 cites W1988680001 @default.
• W2016263931 cites W1991907983 @default.
• W2016263931 cites W1992598325 @default.
• W2016263931 cites W1999786453 @default.
• W2016263931 cites W2000496248 @default.
• W2016263931 cites W2006864608 @default.
• W2016263931 cites W2013436152 @default.
• W2016263931 cites W2026845717 @default.
• W2016263931 cites W2042182057 @default.
• W2016263931 cites W2042204665 @default.
• W2016263931 cites W204282612 @default.
• W2016263931 cites W2043681863 @default.
• W2016263931 cites W2046687563 @default.
• W2016263931 cites W2047127806 @default.
• W2016263931 cites W2062502606 @default.
• W2016263931 cites W2064252525 @default.
• W2016263931 cites W2075297244 @default.
• W2016263931 cites W2075974829 @default.
• W2016263931 cites W2077036239 @default.
• W2016263931 cites W2077195791 @default.
• W2016263931 cites W2093765112 @default.
• W2016263931 cites W2101181764 @default.
• W2016263931 cites W2107200746 @default.
• W2016263931 cites W2108587189 @default.
• W2016263931 cites W2110381463 @default.
• W2016263931 cites W2115129983 @default.
• W2016263931 cites W2118061336 @default.
• W2016263931 cites W2122435775 @default.
• W2016263931 cites W2122921281 @default.
• W2016263931 cites W2150910069 @default.
• W2016263931 cites W2164386461 @default.
• W2016263931 cites W2228339316 @default.
• W2016263931 cites W2417296417 @default.
• W2016263931 cites W4210367804 @default.
• W2016263931 cites W44376639 @default.
• W2016263931 cites W72194072 @default.
• W2016263931 doi "https://doi.org/10.7326/0003-4819-152-3-201002020-00005" @default.
• W2016263931 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3782858" @default.
• W2016263931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20124230" @default.
• W2016263931 hasPublicationYear "2010" @default.
• W2016263931 type Work @default.
• W2016263931 sameAs 2016263931 @default.
• W2016263931 citedByCount "113" @default.
• W2016263931 countsByYear W20162639312012 @default.
• W2016263931 countsByYear W20162639312013 @default.
• W2016263931 countsByYear W20162639312014 @default.
• W2016263931 countsByYear W20162639312015 @default.
• W2016263931 countsByYear W20162639312016 @default.
• W2016263931 countsByYear W20162639312017 @default.
• W2016263931 countsByYear W20162639312018 @default.
• W2016263931 countsByYear W20162639312019 @default.
• W2016263931 countsByYear W20162639312020 @default.
• W2016263931 countsByYear W20162639312021 @default.
• W2016263931 countsByYear W20162639312022 @default.
• W2016263931 countsByYear W20162639312023 @default.
• W2016263931 crossrefType "journal-article" @default.
• W2016263931 hasAuthorship W2016263931A5017029517 @default.
• W2016263931 hasAuthorship W2016263931A5026614969 @default.
• W2016263931 hasAuthorship W2016263931A5040185719 @default.
• W2016263931 hasAuthorship W2016263931A5061725200 @default.
• W2016263931 hasAuthorship W2016263931A5061994382 @default.
• W2016263931 hasAuthorship W2016263931A5065583926 @default.
• W2016263931 hasAuthorship W2016263931A5082109429 @default.
• W2016263931 hasBestOaLocation W20162639312 @default.
• W2016263931 hasConcept C118552586 @default.
• W2016263931 hasConcept C126322002 @default.
• W2016263931 hasConcept C142724271 @default.
• W2016263931 hasConcept C156957248 @default.
• W2016263931 hasConcept C168563851 @default.
• W2016263931 hasConcept C1862650 @default.
• W2016263931 hasConcept C204243189 @default.
• W2016263931 hasConcept C204787440 @default.
• W2016263931 hasConcept C207103383 @default.
• W2016263931 hasConcept C27081682 @default.
• W2016263931 hasConcept C2777843972 @default.
• W2016263931 hasConcept C2779547902 @default.
• W2016263931 hasConcept C2780478649 @default.
• W2016263931 hasConcept C2780687700 @default.
• W2016263931 hasConcept C44249647 @default.
• W2016263931 hasConcept C71924100 @default.
• W2016263931 hasConceptScore W2016263931C118552586 @default.
• W2016263931 hasConceptScore W2016263931C126322002 @default.

• next